Application of citrate anticoagulation with continuous renal replacement therapy at high risk of bleeding patients
10.3760/cma.j.issn.1672-7088.2017.21.003
- VernacularTitle:枸橼酸抗凝对延长高危出血风险患者持续肾脏替代治疗滤器寿命的效果观察
- Author:
Zhenghong XU
;
Hong PAN
;
Qinhong HUANG
;
Yan CAO
;
Jiao ZHOU
;
Haixiang WANG
;
Lan GUO
- Keywords:
Citrate anticoagulation;
Renal replacement therapy;
High risk of bleeding
- From:
Chinese Journal of Practical Nursing
2017;33(21):1609-1611
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of citrate anticoagulation for continuous renal placement therapy (CRRT) in patients at high risk of bleeding. Methods Forty-seven patients who needed to CRRT and were admitted into the department of critical care medicine from January 2015 to October 2016 were enrolled in this study. According to the patient′s actual condition, they were divided into citrate groups (24 cases) and saline group (23 cases). Patients in saline group were given saline wash. The efficacy and safety were compared between the two groups. The filter lifetime, after treatment the activated partial thromboplastin time (APTT), hemoglobin (Hb), blood gas indexes were compared between the two groups. Results The citrate group used 76 filters while the 0.9% sodium chloride group used 87 filters. The average filter lifetime in citrate group was (22.4 ± 12.7) h which was longer than (8.6±3.3) h in 0.9%sodium chloride group (t=9.79, P<0.01). The incidence of coagulation in extracorporeal circulation was 3.9%(3/76) which was lower than 16.1%(14/87) in 0.9%sodium chloride group(χ2=5.20, P<0.05). Conclusions Regional citrate anticoagulation is a safe and effective option for CRRT in patients at high risk of bleeding.
